Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index; 19 of the 43 sources its claims cite were checked for support.
Abstract
Introduction: The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative study of participant experiences from the first randomized placebo-controlled trial of single-dose psilocybin combined with unstructured and non-directive support for individuals with treatment-refractory OCD. Our research explored how participants experienced acute and post-dosing effects, the interrelationships between these effects, and participants’ perspectives on therapeutic change. Materials and methods: We conducted qualitative interviews with 12 participants approximately one month after psilocybin dosing; (six who received psilocybin in the initial randomized placebo-controlled phase, six who received open-label psilocybin following unblinding). We analyzed interview transcripts via interpretative phenomenological analysis (IPA) and engaged in consensus decision-making to arrive at 100% intercoder agreement in the process of abstracting codes into higher-order themes. Results: Four major themes (and several subthemes) emerged from our analysis: 1) Influences on Psilocybin Experience (i.e., Set, Setting); 2) Acute Effects (i.e., Acute perceptual effects, Acute [meta]cognitive effects, Acute emotional effects, Acute impact of OCD, Other acute effects); 3) Post-Dosing Changes in OCD (i.e., Post-dosing changes in symptoms, Post-dosing changes in perceptions of OCD); as well as 4) Post-Dosing Changes Beyond OCD Symptoms (i.e., Post-dosing [meta]cognitive changes, Other post-dosing changes). Meaningful interrelationships among codes, subthemes, and themes were the norm. Discussion: Our findings highlight the moderate to strong influences of set and setting in the nature and trajectory of participants’ psilocybin experiences. We also uncovered acute, synergistic visual/perceptual, emotional/psychological, and physiological/somatic effects that map onto those commonly reported in prior psilocybin trials for other closely related indications. However, these acute effects tended to occur at lower intensities (i.e., ‘partial’ experiences) potentially due to acute interference by OCD symptoms. Certain acute and post-dosing (meta)cognitive and behavioral effects also map onto putative mechanisms of action in evidence-based psychotherapy for OCD (e.g., exposure and response prevention [ERP] and acceptance and commitment therapy [ACT]). These findings yielded hypotheses for future investigation, and point toward potential integration of psilocybin with structured psychotherapy approaches for OCD. Copyright © 2025 Ching, Stahnke, Shnayder, Agin-Liebes, Adams, Amoroso, Baiz, Belser, Bohner, Burke, D’Amico, DePalmer, Eilbott, Fram, Grazioplene, Hokanson, Jankovsky, Kichuk, Martins, Purohit, Schaer, Sierra, Witherow, Pittenger and Kelmendi.
Overview
CoChat Summary
## TL;DR
This qualitative IPA study analyzed 12 post-dosing interviews from a randomized, double-blind, placebo-controlled psilocybin trial for treatment-refractory OCD and found that set/setting strongly shaped experiences. Participants commonly reported acute perceptual, emotional, and (meta)cognitive effects, with heterogeneous post-dosing OCD changes and several parallels to ACT/ERP-style processes.
## Key findings
- The analysis identified 4 major themes: (1) Influences on Psilocybin Experience, (2) Acute Effects, (3) Post-Dosing Changes in OCD, and (4) Post-Dosing Changes Beyond OCD Symptoms.
- The sample showed heterogeneous OCD outcomes after dosing: some participants had full remission of obsessions/compulsions (e.g., Participants 6 and 8), some had brief total symptom relief with symptoms returning days later (Participants 13, 16, 17), and others had persistent but positively changed relationships with their symptoms.
- The paper reports moderate to strong influences of set and setting, with support from facilitators, the room, and music shaping the trajectory of the experience; these factors were described as instrumental for trust, comfort, and insight.
- Acute experiences were often “partial” mystical experiences rather than full ones, which the authors suggest may reflect OCD interference; they also note many acute and post-dosing processes resembled ACT and ERP mechanisms such as decentering, mindfulness, cognitive defusion, experiential approach, and reduced avoidance.
## Methods
- Qualitative study nested within the first randomized, double-blind, placebo-controlled trial of single-dose psilocybin for treatment-refractory OCD, with unstructured, non-directive psychological support; the paper also references an open-label phase after unblinding.
- Conducted semi-structured interviews with 12 treatment completers approximately one month after psilocybin dosing: 6 from the initial randomized placebo-controlled phase and 6 who later received open-label psilocybin.
- Analyzed transcripts using interpretative phenomenological analysis (IPA) with consensus decision-making and 100% intercoder agreement; the authors say data saturation stopped producing new categories after the 10th interview.
## Limitations
- The paper states limitations of retrospective data collection at a single timepoint rather than real-time micro-longitudinal assessment, which could better capture change over time.
- The authors note the convenience sample of the first 12 completers may not represent the full range of psilocybin experiences, especially those who withdrew or declined interview.
- The paper also states the sample was demographically homogenous, limiting transferability; more diverse narratives are needed to better capture the role of identity/set in psilocybin effects.
- Evident from the text: because the study is qualitative and focused on 12 participants, it cannot support causal claims about psilocybin’s effects on OCD.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
8 Valid · 1 Not valid · 5 Not checked · 64 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings demonstrate that psilocybin effects do not occur in an intraindividual vacuum, but rather is subjected to complex, synergistic interactions with elements outside of the self and the drug (60, 61).”
§ Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis > Discussion
What the sources say
- Partly supportedcites [60] Ching, 2024, Capturing synergy holistically in psychedelic clinical trials: assessing processes in addition to outcomes, Clin Pharmacol Ther sourceExperimental — accuracy not yet measured
In “Capturing Synergy Holistically in Psychedelic Clinical Trials” (page unavailable), the authors discuss putative interactions between psychedelics and interventions, including psychotherapy, and argue that synergy should be assessed as a process. The passage does not establish that psilocybin effects are subject to such interactions; it discusses possibilities for psychedelics generally. (LLM, conf=0.82)
- Partly supportedcites [61] Dworkin, 2023, Psychedelics and psychotherapy: is the whole greater than the sum of its parts, Clin Pharmacol Ther sourceExperimental — accuracy not yet measured
The “Randomized Trials of Psychedelics” section says psychedelic pharmacology has been suggested to interact synergistically with the context of administration, including psychotherapy. But “Evaluating Synergy” calls this a plausible hypothesis that needs testing, not a demonstrated effect; the citing sentence overstates that certainty. (LLM, conf=0.86)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“in our trial, participants rarely described the full array of acute effects that together prototypically constitute ‘full mystical experiences’ described in landmark studies (e.g., psilocybin for existential distress or depression) (21, 63).”
§ Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis > Discussion
What the sources say
- Supportedcites [21] Griffiths, 2008, Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later, J Psychopharmacol source
The Methods section, under ‘Measures assessed 7 hours after drug administration,’ defines a complete mystical experience using six domains, including unity, transcendence, sacredness and positive mood. The cited paper thus supports the description of the full array of effects; the statement that participants rarely described them refers to the citing authors’ own trial, not this source. (LLM, conf=0.88)
- Supportedcites [63] Ko, 2022, Psychedelics, mystical experience, and therapeutic efficacy: a systematic review, Front Psychiatry source
The Introduction (page unavailable) describes the dimensions of mystical experience and explains how studies identify a ‘complete’ experience. The Results sections (page unavailable) discuss psilocybin studies of cancer-related distress and depression. The statement that experiences were rare in the citing authors’ own trial is their observation, not a finding attributed to this review. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In this study, we conducted a qualitative analysis of post-dosing interview data from 12 completers in the first, randomized, double-blind, single-dose, placebo-controlled trial of psilocybin for OCD (31, 33).”
§ Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis > Discussion
What the sources say
- Supportedcites [31] Ching, 2023, Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: Protocol for a randomized, double-blind, placebo-controlled, non-crossover trial, Front Psychiatry source
The Introduction (Objectives and hypotheses; page unavailable) identifies this as a randomized, double-blind, single-dose, placebo-controlled psilocybin trial for OCD. The Discussion calls it the first randomized, placebo-controlled trial for OCD, and the Method (Schedule of trial activities; page unavailable) plans post-dosing qualitative interviews. The 12-completer analysis is described as the citing authors’ own work, not a finding attributed to this protocol. (LLM, conf=0.90)
- Not matchedcites [33] Kelmendi, Psilocybin for treatment-resistant OCD: a randomized controlled trial
Its entry has no title and year that we can search by.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these acute effects tended to occur at lower intensities (i.e., ‘partial’ experiences)”
§ Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis > Abstract > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four major themes (and several subthemes) emerged from our analysis: 1) Influences on Psilocybin Experience (i.e., Set, Setting); 2) Acute Effects (i.e., Acute perceptual effects, Acute [meta]cognitive effects, Acute emotional effects, Acute impact of OCD, Other acute effects); 3) Post-Dosing Changes in OCD (i.e., Post-dosing changes in symptoms, Post-dosing changes in perceptions of OCD); as well”
- Also stated in: § Results · plain
“Figure 3 illustrates emergent codes, subthemes, and major themes (i.e., Influences on Psilocybin Experience; Acute Effects; Post-Dosing Changes in OCD; Post-Dosing Changes Beyond OCD Symptoms) from our analysis”
§ Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Results · plain
37 more claims
Create a free account to see all 78 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 13
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis > Results > Acute effects
“Participant 17 described another profound visual experience of different paths in life she could take in spite of frequently feeling disempowered by her OCD symptoms.”
§ Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis > Results > Post-dosing changes in OCD
“Interestingly, Participant 17 expressed non-ontological beliefs about his OCD post-dosing; he reiterated that psilocybin reinforced his pre-existing ideas about “how to live and manage OCD in a more adaptive way.””
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Hayes, S. C., Wilson, K. G., Gifford, E. V., Follette, V. M., & Strosahl, K. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.64.6.1152 · Cited by 3,595 · cited 1×
“…(meta)cognitive experiences were also examples of experiential approach (see next section), or the process of fl exibly ‘ going with ’ arising experiences or ‘ letting them be, ’ instead of rigidly controlling, eliminating, or avoiding such experiences (i.e., experiential avoidance) (49 – 52).”
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771 · cited 3×
“…as distress, irritation, anger, fear, doubt, and/or anxiety/panic, for instance, when OCD intruded upon their psilocybin experience (Participants 3, 15), when disturbed by visualizations (Participants 6, 10, 17), when misinterpreted by a facilitator (Participant 12), or in anticipation of…”
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
Essentials of interpretative phenomenological analysis.
Smith, J. A., & Nizza, I. E. (2022) · doi:10.1037/0000259-000 · Cited by 1,041
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Carpenter, J. K., Andrews, L. A., Witcraft, S. M., Powers, M. B., Smits, J. A. J., & Hofmann, S. G. (2018) · Depression and Anxiety · doi:10.1002/da.22728 · Cited by 846 · cited 1×
“…selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavior therapy with exposure and response prevention (CBT/ERP) are helpful for some (7 – 11), they continue to be limited by low remission (12 – 16) and high relapse rates (17, 18), highlighting the need for novel therapeutic…”
Experiential avoidance as a functional dimensional approach to psychopathology: An empirical review
Chawla, N., & Ostafin, B. (2007) · Journal of Clinical Psychology · doi:10.1002/jclp.20400 · Cited by 805
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Schweiger, D. M., Sandberg, W. R., & Ragan, J. W. (1986) · Academy of Management Journal · doi:10.2307/255859 · Cited by 682 · cited 1×
“Coders used a consensus decision-making approach (44) to reach 100% intercoder agreement at every phase of the analytical process.”
Öst, L.-G., Havnen, A., Hansen, B., & Kvale, G. (2015) · Clinical Psychology Review · doi:10.1016/j.cpr.2015.06.003 · Cited by 655
Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817709585 · Cited by 589 · cited 3×
“These emotions largely cohered with previous observations in other psilocybin studies (36 – 42).”
InfluentialCuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2013) · World Psychiatry · doi:10.1002/wps.20038 · Cited by 540
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Hartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · cited 1×
“Our fi ndings regarding pre-dosing factors highlight the moderate to strong in fl uence of extra-pharmacological factors of set and setting (53, 54) in the nature and trajectory of participants ’ psilocybin experiences.”
Constructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 1×
“Our fi ndings regarding pre-dosing factors highlight the moderate to strong in fl uence of extra-pharmacological factors of set and setting (53, 54) in the nature and trajectory of participants ’ psilocybin experiences.”
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347 · cited 1×
“Psilocybin (4-phosphryloxy-N,N-dimethyltryptamine) is a serotonergic classic psychedelic (19 – 25) that has been examined in combination with psychological support as a promising treatment option in clinical trials for various disorders (26 – 28).”
Soomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342
Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., Guss, J., Bossis, A., & Ross, S. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817706884 · Cited by 311
Self-citationPsychedelics, mystical experience, and therapeutic efficacy: a systematic review
Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.917199 · Cited by 306 · cited 1×
“…and other protocol or methodological differences, in our trial, participants rarely described the full array of acute effects that together prototypically constitute ‘ full mystical experiences ’ described in landmark studies (e.g., psilocybin for existential distress or depression) (21, 63).”
Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780612 · Cited by 285
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
The hidden therapist: evidence for a central role of music in psychedelic therapy
Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., Roseman, L., Feilding, A., Nutt, D., & Carhart-Harris, R. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4820-5 · Cited by 267
Reid, J. E., Laws, K. R., Drummond, L., Vismara, M., Grancini, B., Mpavaenda, D., & Fineberg, N. A. (2021) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2021.152223 · Cited by 266
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00748-y · Cited by 224
Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N., Terrana, S., Friedman, H. L., Guss, J., Bossis, A. P., & Ross, S. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167817715966 · Cited by 195
Self-citationQuality of Life in Obsessive-Compulsive Disorder: Impact of the Disorder and of Treatment
Subramaniam, M., Soh, P., Vaingankar, J. A., Picco, L., & Chong, S. A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0056-z · Cited by 185 · cited 1×
“OCD is chronically disabling (2 – 4), stigma-inducing (5), and associated with high latencies to treatment (6).”
Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184
Sloshower, J., Guss, J., Krause, R., Wallace, R. M., Williams, M. T., Reed, S., & Skinta, M. D. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.002 · Cited by 171
Twohig, M. P., Abramowitz, J. S., Smith, B. M., Fabricant, L. E., Jacoby, R. J., Morrison, K. L., Bluett, E. J., Reuman, L., Blakey, S. M., & Ledermann, T. (2018) · Behaviour Research and Therapy · doi:10.1016/j.brat.2018.06.005 · Cited by 156
Akbari, M., Seydavi, M., Hosseini, Z. S., Krafft, J., & Levin, M. E. (2022) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2022.03.007 · Cited by 155
Quality of life in obsessive compulsive disorder
Macy, A. S., Theo, J. N., Kaufmann, S. C. V., Ghazzaoui, R. B., Pawlowski, P. A., Fakhry, H. I., Cassmassi, B. J., & IsHak, W. W. (2013) · CNS Spectrums · doi:10.1017/s1092852912000697 · Cited by 150
Gukasyan, N., & Nayak, S. M. (2022) · Transcultural Psychiatry · doi:10.1177/1363461520983684 · Cited by 150 · cited 1×
“Additionally, facilitator support, in the form of words of encouragement, reassurance, active listening, or brief supportive touch, was instrumental at times for certain participants to arrive at key insights regarding their psilocybin experience (57 – 59).”
Trauma and posttraumatic stress disorder in treatment-resistant obsessive-compulsive disorder
Gershuny, B. S., Baer, L., Parker, H., Gentes, E. L., Infield, A. L., & Jenike, M. A. (2008) · Depression and Anxiety · doi:10.1002/da.20284 · Cited by 139 · cited 1×
“Future research can also attempt to compare psilocybin treatment outcomes between individuals with OCD with and without trauma exposure, given emerging research on the role of trauma exposure impacting OCD symptom course and treatment response (84 – 87).”
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122 · cited 10×
“Participants 8, 10, and 13 believed that they came in touch with “ universal truth, ” to which they surrendered, to varying extents.”
InfluentialNew Directions in the Cognitive-Behavioral Treatment of OCD: Theory, Research, and Practice
Abramowitz, J. S., Blakey, S. M., Reuman, L., & Buchholz, J. L. (2018) · Behavior Therapy · doi:10.1016/j.beth.2017.09.002 · Cited by 98
Trauma-related obsessive–compulsive disorder: a review
Dykshoorn, K. L. (2014) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2014.905207 · Cited by 96 · cited 1×
“Future research can also attempt to compare psilocybin treatment outcomes between individuals with OCD with and without trauma exposure, given emerging research on the role of trauma exposure impacting OCD symptom course and treatment response (84 – 87).”
Exposure therapy for obsessive-compulsive disorder: an optimizing inhibitory learning approach
Arch, J. J., & Abramowitz, J. S. (2015) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2014.12.002 · Cited by 96
Bloch, M. H., Green, C., Kichuk, S. A., Dombrowski, P. A., Wasylink, S., Billingslea, E., Landeros-Weisenberger, A., Kelmendi, B., Goodman, W. K., Leckman, J. F., et al. (2013) · Depression and Anxiety · doi:10.1002/da.22103 · Cited by 94
Self-citationThe effect of trauma on the severity of obsessive-compulsive spectrum symptoms: a meta-analysis
Miller, M. L., & Brock, R. L. (2017) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2017.02.005 · Cited by 93
Issari, Y., Jakubovski, E., Bartley, C. A., Pittenger, C., & Bloch, M. H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09758 · Cited by 92
Self-citationA meta-analysis of relapse rates in cognitive-behavioral therapy for anxiety disorders
Levy, H. C., O’Bryan, E. M., & Tolin, D. F. (2021) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2021.102407 · Cited by 91
Schneier, F. R., Feusner, J., Wheaton, M. G., Gomez, G. J., Cornejo, G., Naraindas, A. M., & Hellerstein, D. J. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.031 · Cited by 81
The therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74 · cited 2×
“…emotional/psychological, and physiological/somatic effects that map onto those commonly reported in psilocybin clinical trials for other closely related indications (e.g., body dysmorphic disorder, depression, illness-related anxiety) (26 – 28), as well as in healthy control studies (22, 62).”
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Mosurinjohn, S. C., Roseman, L., & Girn, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1077311 · Cited by 74
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
Twohig, M. P., Vilardaga, J. C. P., Levin, M. E., & Hayes, S. C. (2015) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2015.07.001 · Cited by 72
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)
Zeifman, R. J., Spriggs, M. J., Kettner, H., Lyons, T., Rosas, F. E., Mediano, P. A. M., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Scientific Reports · doi:10.1038/s41598-023-28111-3 · Cited by 69 · cited 1×
“…interesting deviation from what may be predicted by the REBUS model, which hypothesizes that relaxed beliefs under the in fl uence of psychedelics are likely to translate to long-term reconstitution, revision, or change in an individual ’ s belief systems and broader personality structure (80, 81).”
Predictors of response to cognitive behaviour therapy for obsessive-compulsive disorder
Kyrios, M., Hordern, C., & Fassnacht, D. B. (2015) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2015.07.003 · Cited by 68
A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder
Stein, D. J., Koen, N., Fineberg, N., Fontenelle, L. F., Matsunaga, H., Osser, D., & Simpson, H. B. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0268-9 · Cited by 65
Breeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58
Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Agin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024) · Journal of Humanistic Psychology · doi:10.1177/00221678211022949 · Cited by 51
Self-citationAngelakis, I., & Pseftogianni, F. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.062 · Cited by 47
Philip, J., & Cherian, V. (2020) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2020.100603 · Cited by 43
Obsessive Beliefs Predict Cognitive Behavior Therapy Outcome for Obsessive Compulsive Disorder
Adams, T. G., Riemann, B. C., Wetterneck, C. T., & Cisler, J. M. (2012) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2011.621969 · Cited by 38 · cited 1×
“This bears out in the ACT and ERP literature on moderators and mediators of change in OCD treatment, in which symptom change and (meta)cognitive and behavioral change are shown to form a robust feedback loop feed in the cycle of symptom recovery (69 – 73).”
Self-citationThompson, B. L., Twohig, M. P., & Luoma, J. B. (2021) · Behavior Therapy · doi:10.1016/j.beth.2020.04.011 · Cited by 36
McDonald, S., Melkonian, M., Karin, E., Dear, B. F., Titov, N., & Wootton, B. M. (2023) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465823000103 · Cited by 31
A systematic review of public stigma attributes and obsessive–compulsive disorder symptom subtypes.
Ponzini, G. T., & Steinman, S. A. (2021) · Stigma and Health · doi:10.1037/sah0000310 · Cited by 29 · cited 6×
“More commonly, for others (Participants 3, 5, 9, 12, 18), their relationship with their obsessions evolved in positive ways in spite of persisting obsessional severity and content (see sections below for more).”
InfluentialChing, T. H. W., Grazioplene, R., Bohner, C., Kichuk, S. A., DePalmer, G., D’Amico, E., Eilbott, J., Jankovsky, A., Burke, M., Hokanson, J., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1178529 · Cited by 29
Buot, A., Pallares, C., Oganesyan, A., Dauré, C., Bonnelle, V., Burguière, E., Dos Santos, J. F. A., N’Diaye, K., Ljuslin, M., Smith, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39812-0 · Cited by 28
Psychedelia: The interplay of music and psychedelics
Jerotic, K., Vuust, P., & Kringelbach, M. L. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15082 · Cited by 28 · cited 1×
“The playlist contained evocative music that helped shape certain participants ’ reported experiences (55, 56).”
Ching, T. H. W. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.017 · Cited by 27
Self-citationAcceptance and Commitment Therapy in Obsessive–Compulsive Disorder: A Case Study
Philip, J., & Cherian, V. (2021) · Indian Journal of Psychological Medicine · doi:10.1177/0253717621996734 · Cited by 25
Costa, D. L. D. C., Polpo, A., Pereira, C. A. D. B., Torres, A. R., dos Santos, A. C., Requena, G. D. L., Ferrão, Y. A., do Rosário, M. C., Miguel, E. C., Simpson, H. B., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114567 · Cited by 24
Gershkovich, M., Deacon, B. J., & Wheaton, M. G. (2018) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2018.03.001 · Cited by 19
Luoma, J. B., Allen, L. R., Gold, V., & Stauffer, C. S. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0033 · Cited by 18
Psychedelics and psychotherapy: is the whole greater than the sum of its parts
Dworkin, R. H., McDermott, M. P., Nayak, S. M., & Strain, E. C. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3050 · Cited by 17
Wislocki, K. E., Kratz, H. E., Martin, G. J., & Becker‐Haimes, E. M. (2022) · Child Psychiatry & Human Development · doi:10.1007/s10578-022-01352-5 · Cited by 16
Longitudinal course of pharmacotherapy in obsessive–compulsive disorder
Grant, J. E., Mancebo, M. C., Weinhandl, E., Odlaug, B. L., Eisen, J. L., & Rasmussen, S. A. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283613e4d · Cited by 12
Neurotransmitter Dysregulation in OCD
Graat, I., Figee, M., & Denys, D. A. J. P. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190228163.003.0025 · Cited by 12
Ching, T. H. W., Williams, M. T., Reed, S. J., Kisicki, M. D., Wang, J. B., Yazar‐Klosinski, B., Emerson, A., & Doblin, R. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221076993 · Cited by 11
Self-citationChing, T. H. W., Amoroso, L., Bohner, C., D’Amico, E. J., Eilbott, J. A., Entezar, T., Fitzpatrick, M., Fram, G., Grazioplene, R. G., Hokanson, J., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1278823 · Cited by 10
Self-citationBuchholz, J. L., Abramowitz, J. S., Hellberg, S. N., Ojalehto, H. J., & Twohig, M. P. (2023) · Journal of Cognitive Psychotherapy · doi:10.1891/jcp-2021-0004 · Cited by 9
Luoma, J. B., & LeJeune, J. T. (2025) · The American Journal of Bioethics · doi:10.1080/15265161.2024.2433425 · Cited by 9
Ching, T. H. W., Kichuk, S. A., DePalmer, G., Pittenger, C., & Kelmendi, B. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/85s9p · Cited by 8
Self-citationChing, T. H. W., Grazioplene, R., Pittenger, C., & Kelmendi, B. (2023) · doi:10.31234/osf.io/ba42z · Cited by 6
Self-citationChing, T. H. W., Pinciotti, C. M., & Farrell, N. R. (2022) · Scandinavian Journal of Psychology · doi:10.1111/sjop.12896 · Cited by 4 · cited 1×
“Thus, psilocybin-occasioned changes in disorder-related causal attributions may need to be more rigorously assessed in future research, especially in light of emerging psychotherapy literature about the association between causal explanations and treatment response in OCD (82, 83).”
Self-citationChing, T. H. W., & Shnayder, S. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3129 · Cited by 2 · cited 1×
“These fi ndings demonstrate that psilocybin effects do not occur in an intraindividual vacuum, but rather is subjected to complex, synergistic interactions with elements outside of the self and the drug (60, 61).”
Self-citation
Research works printed but not linked: 3
- Hayes, 2016, Acceptance and commitment therapy: The process and practice of mindful change
- Yaden, 2022, The varieties of
- Thompson, 2023, ACT-informed exposure for anxiety: creating effective, innovative, and values-based exposures using acceptance and commitment therapy
Cited by
Moreno, F. A., Ehrmann, K., Wiegand, C. B., Dunne, R., Prickett, J. I., Bayze, B., & Allen, J. J. B. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424214 · Cited by 10
“The study reported post-exposure experiences resulting in variable improvements in obsessions and compulsions among some participants, although formal quantitative analysis was not reported (Ching et al., 2025).”
Drange, S., Cohen, J., Johansen, S. S., Dunkley, B. T., & Palner, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1819962 · Cited by 2
Shnayder, S., Agin-Liebes, G., Hubert, T., Ching, T. H. W., Hokanson, J., Pittenger, C., Kelmendi, B., & Adams, T. G. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1799543
Self-citationJalalian-Javadpour, M., Yekta, B. G., Reyhani, N., Hajizamani, S., Azizi, A., Azad, N. K., Mohammadi, H., & Vaseghi, S. (2026) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2026.101098
What About Psycholytic Therapy? A Historical Revisiting of Psychedelics Assisting Psychotherapy
Zaher, I., & Richard, J. (2026) · Psychedelic Medicine · doi:10.1177/28314425261455416
Metadata
- Authors
- Ching, T. H. W., Stahnke, B., Shnayder, S., Agin-Liebes, G., Adams, T. G., Amoroso, L., Baiz, O., Belser, A., Bohner, C., Burke, M., D’Amico, E., DePalmer, G., Eilbott, J., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Purohit, P., Schaer, H., Sierra, Y. P., Witherow, C., Pittenger, C., & Kelmendi, B.
- Affiliations
- Yale University (US)
- East Tennessee State University (US)
- New York University (US)
- Corresponding author
- Ching, T. H. W.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2025-12-10
- Volume
- 16
- Pages
- 1726818-1726818
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC12728583
- OpenAlex
- W7113899315
- Cited by
- 6
- References
- 83
- Citations by year
- 2026: 6
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Yale University
- Usona Institute
- National Institute of Mental Health (K23MH122777)
- Yale Center for Clinical Investigation, Yale School of Medicine
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, obsessive-compulsive disorder, treatment-refractory OCD, subjective effects, set and setting, emotional impact, therapeutic change, psychedelic-assisted psychotherapy, exposure and response prevention, acceptance and commitment therapy, participant experiences
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.